GLP-1 medications can cost hundreds of dollars a month even at the makers' cash prices, and more than $1,000 at full list price, so insurance coverage isn't just a nice-to-have. It's often the deciding factor in whether treatment is affordable. Coverage is messy and varies wildly depending on your plan, your diagnosis, and which specific medication you're prescribed. (See our GLP-1 insurance coverage guide.) (See our savings calculator.)
The Diabetes vs. Weight Loss Problem
If you have type 2 diabetes, your odds of getting coverage are much better. Ozempic and Mounjaro are both FDA-approved for diabetes, and most commercial insurance plans, Medicare Part D, and Medicaid programs cover them for this indication. You'll still deal with prior authorizations and step therapy requirements, but the path exists. (See our Medicaid GLP-1 coverage.)
If your primary diagnosis is obesity or overweight, coverage gets significantly harder. Wegovy and Zepbound are FDA-approved specifically for weight management, but many insurers still classify weight loss medications as "lifestyle" drugs and exclude them. Some plans cover them and many do not, so check yours.
Medicare and Medicaid
For more than twenty years, federal law has barred Medicare drug plans from paying for drugs prescribed purely for weight loss, and that law has not changed. Since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge has covered Wegovy, the Zepbound KwikPen and Foundayo for weight loss at a flat $50 a month, and it runs through December 31, 2027. You need to be in a Medicare drug plan, meet the BMI rules, and get prior authorization. Ozempic and Mounjaro are not on the list.
One catch worth knowing early: if you have type 2 diabetes, moderate to severe sleep apnea, or a form of fatty liver disease called noncirrhotic MASH with moderate to advanced liver scarring, the Bridge is not for you. Your regular Part D coverage may pay for a GLP-1 instead, so ask your provider about that route.
Medicaid is a different picture in every state. Coverage is required for type 2 diabetes, for cardiovascular disease, and for moderate to severe sleep apnea. Covering GLP-1s for obesity on its own is optional, and only a minority of states do it. Required does not mean automatic either, since prior authorization still applies. Our Medicaid GLP-1 coverage guide has the state by state detail.
Commercial Insurance: What to Expect
Even when your commercial plan technically covers GLP-1 medications, expect hoops to jump through:
- Prior authorization: your doctor submits documentation proving medical necessity
- Step therapy: some plans require you to try cheaper medications first
- BMI requirements: typically BMI 30+ or 27+ with a comorbidity like hypertension
- Specialist requirements: some plans want the prescription from an endocrinologist or obesity medicine specialist
With coverage, what you pay depends on your plan tier and whether the manufacturer's savings card applies. Without coverage, the list price runs from about $500 to about $1,350 a month depending on the drug and dose. Both makers also offer self-pay prices directly to cash-paying patients: Wegovy pens are $349 a month through NovoCare, the Wegovy pill starts at $149, and Zepbound through LillyDirect runs $299 to $699 depending on the dose. Offers and terms change, so check the maker's site. (See our GLP-1 pricing guide.) (See our BMI calculator.)
When You're Denied Coverage
A denial isn't necessarily the end. Your provider can file an appeal with supporting medical documentation, things like your BMI history, failed diet attempts, and weight-related health conditions. Many clinics have staff who handle these appeals routinely. Some patients get approved on appeal after an initial denial.
If insurance isn't an option, alternatives include manufacturer savings programs, buying direct from the manufacturer at a cash price, and weight loss clinics that offer bundled pricing. Compounded versions are not FDA-approved, and since the shortages ended pharmacies generally may not make copies of these drugs; our compounding guide explains what changed.
Which Medications Get Covered Most Often
Insurers treat each drug differently, and it is worth knowing which one your plan prefers before your appointment:
- Wegovy has the widest commercial coverage of the weight loss drugs. It was the first semaglutide approved specifically for weight management. Prior authorization is still almost always required.
- Zepbound is picking up formulary coverage, and some insurers prefer it. If your plan turns down one of the two, ask about the other. Plenty of plans cover only one.
- Ozempic and Mounjaro are approved for type 2 diabetes, not weight loss. A plan will usually cover them with a diabetes diagnosis and deny them when the prescription says weight loss. Worth raising with your provider before the claim goes in.
Questions to Ask Before Your Appointment
Call the number on the back of your insurance card and ask these five things. Having the answers first saves a lot of back and forth:
- Does my plan cover anti-obesity medications at all?
- Which ones are on formulary? Name Wegovy and Zepbound specifically.
- What is my copay or coinsurance for a specialty medication?
- Is prior authorization required, and what documents do you need?
- Is there a step therapy rule, meaning I have to try something cheaper first?
How a Good Clinic Helps
Experienced GLP-1 clinics deal with insurance companies daily. They know which plans cover what, how to write prior authorizations that get approved, and when an appeal is worth pursuing. This is one of the underrated advantages of going through a dedicated weight loss clinic versus a general practitioner who prescribes these medications occasionally.
Search our clinic directory to find providers near you. Many clinics offer free consultations where they'll check your specific insurance coverage before you commit. For more on what treatment costs look like, read our guide on Mounjaro pricing or compare telehealth vs. in-person clinics to find the most affordable option. (See our telehealth GLP-1 providers.)